TF and cancer: The altered glycosylation observed in cancer cells leads to the expression of modified tumor-associated glycans (TAG) such as Thomsen-Friedenreich antigen (Galβ1-3GalNAcα/β-O-Ser/Thr; TF, CD176) that may be autoimmunogenic and may be recognized by autoantibodies [1–6].